Author

Tom Lillie

Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

2008 · Robert E. Smith, Matti S. Aapro, et al. · Journal of Clinical Oncology · 211

PDF

Safety and Efficacy of Darbepoetin Alfa in Previously Untreated Extensive-Stage Small-Cell Lung Cancer Treated With Platinum Plus Etoposide

2008 · Robert Pirker, Rodryg A. Ramlau, et al. · Journal of Clinical Oncology · 114

Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE)

2023 · Marwan Fakih, Wael Harb, et al. · Journal for ImmunoTherapy of Cancer · 49

PDF

Darbepoetin Alfa Administered Every Three Weeks Is Effective for the Treatment of Chemotherapy-Induced Anemia

2006 · Ralph Boccia, Imtiaz A. Malik, et al. · The Oncologist · 40

Treating Anemia of Cancer with Every-4-Week Darbepoetin Alfa: Final Efficacy and Safety Results from a Phase II, Randomized, Double-Blind, Placebo-Controlled Study

2008 · David Gordon, Gwen Nichols, et al. · The Oncologist · 24

Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia

2009 · Enrique Hernandez, Peter Ganly, et al. · Current Medical Research and Opinion · 23

First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments

2024 · Aung Naing, Danny Khalil, et al. · Journal for ImmunoTherapy of Cancer · 15

PDF

The Effectiveness of Darbepoetin Alfa Administered Every 3 Weeks on Hematologic Outcomes and Quality of Life in Older Patients With Chemotherapy-Induced Anemia

2007 · Ralph Boccia, Tom Lillie, et al. · The Oncologist · 15

1120 POSTER Evaluation of the association between hemoglobin (Hb) events and safety outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA): an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials (RCTs) of darbepoetin alfa (DA)

2007 · J. Glaspy, A. Österborg, et al. · European Journal of Cancer Supplements · 13

Treating Anemia of Cancer with Darbepoetin Alfa Administered Every 4 Weeks: Final Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Cancer Patients Not Receiving Chemotherapy and/or Radiotherapy.

2006 · David H. Gordon, Gwen Nichols, et al. · Blood · 13

A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies

2023 · Danny N. Khalil, Isabel Prieto González-Albo, et al. · Investigational New Drugs · 10

PDF

762 First-in-human phase 1a study of NG-641, a tumour-selective vector expressing a FAP-TAc bispecific antibody and immune enhancer module, in patients with metastatic/advanced epithelial tumours (STAR)

2022 · George Simon, Vivek Subbiah, et al. · Regular and Young Investigator Award Abstracts · 10

PDF

Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial

2010 · Lee Schwartzberg, Ronald Burkes, et al. · BMC Cancer · 7

PDF

Effects of Dose Adjustment Rules on Safety during Erythropoietic Therapy: A Retrospective Analysis of Darbepoetin alfa Administered Either Every 3 Weeks or Weekly.

2005 · Michael Hedenus, Jean-Luc Canon, et al. · Blood · 7

PD6-3-6: A phase 3 randomized, double blind, placebo-controlled study of patients with previously untreated extensive-stage small cell lung cancer (SCLC) treated with platinum plus etoposide chemotherapy with or without darbepoetin alfa

2007 · Robert Pirker, Rodryg Ramlau, et al. · Journal of Thoracic Oncology · 5

Abstract CT214: A multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA)

2022 · Tom Lillie, Eileen Parkes, et al. · Cancer Research · 4

437 A multicentre phase 1b study of NG-641, a novel transgene-armed and tumour-selective adenoviral vector, and pembrolizumab as neoadjuvant treatment for squamous cell carcinoma of the head and neck

2021 · Christian Ottensmeier, Mererid Evans, et al. · Regular and Young Investigator Award Abstracts · 4

PDF

1104 POSTER Patient-level integrated analysis of data from 6 randomized, double-blind, placebo-controlled trials of darbepoetin alfa (DA) in patients (pts) with chemotherapy-induced anemia (CIA)

2007 · H. Ludwig, J. Crawford, et al. · European Journal of Cancer Supplements · 3

Impact of Darbepoetin Alfa on Transfusion, Hemoglobin Response, and Survival in Cancer Patients with Chemotherapy-Induced Anemia: Results of a Meta-Analysis of Randomized, Placebo-Controlled Trials.

2005 · Nick Freemantle, Bin Yao, et al. · Blood · 3

Abstract CT213: A multicenter phase 1a/b study of NG-350A, a tumor-selective anti-CD40-antibody expressing adenoviral vector, and pembrolizumab in patients with metastatic or advanced epithelial tumors (FORTIFY)

2022 · Tom Lillie, Mark O'Hara, et al. · Cancer Research · 2

342 Combining enadenotucirev and nivolumab increased tumour immune cell infiltration/activation in patients with microsatellite-stable/instability-low metastatic colorectal cancer in a phase 1 study

2021 · David Krige, Marwan Fakih, et al. · Regular and Young Investigator Award Abstracts · 2

PDF

329 Prolonged overall survival (OS) in patients with metastatic colorectal cancer (mCRC) in SPICE, a phase I study of enadenotucirev in combination with nivolumab

2020 · Tom Lillie, Andrew Stone, et al. · Regular and Young Investigator Award Abstracts · 2

PDF

The Effect of Hemoglobin (Hb) Level at ESA Initiation on Outcomes in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA): A Patient-Based Meta-Analysis from 6 Randomized, Placebo-Controlled Trials (RCTs) of Darbepoetin alfa (DA).

2007 · J. Crawford, D. Henry, et al. · Blood · 2

A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia

2007 · Lee S. Schwartzberg, Timothy P. Rearden, et al. · The Journal of Supportive Oncology · 2

1141 POSTER Evaluation of extended dosing intervals versus weekly dosing of darbepoetin alfa (DA): A phase 2 study in cancer patients (pts) with chemotherapy-induced anemia (CIA)

2007 · T. Rearden, L. Schwartzberg, et al. · European Journal of Cancer Supplements · 1

Works count: 39

Citation count: 583

H-index: 10

I10-index: 12